Trial reportEuropean journal of nuclear medicine and molecular imaging2017
Individualised
Trial report in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04954820 (A Prospective Randomized Phase II Study Assess the Schema of Retreatment With Lutathera®), which is not on this map. Cited by 107 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Randomized Phase II Study Assess the Schema of Retreatment With Lutathera® ([177LU]LU-DOTA-TATE) in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor
Who cites it
107 citing papers in PubMed, 1 synthesis or guideline pooled it, 199 citations in OpenAlex.
- Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Safety and dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Trial
- A phase I/II study of the safety and efficacy of [European journal of nuclear medicine and molecular imaging · 2023Trial
- Trial
- Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-basedEuropean journal of nuclear medicine and molecular imaging · 2022Trial
- Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up.Neuroendocrinology · 2021Trial
- PersonalizedEuropean journal of nuclear medicine and molecular imaging · 2019Trial
- Trial
- Comparative assessment of KDIGO and CTCAE criteria for detecting renal function deterioration after peptide receptor radionuclide therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Long-term toxicity of tandem radioligand therapy using [European journal of nuclear medicine and molecular imaging · 2026Article
- Assessment of potential nephrotoxicity biomarkers after [Scientific reports · 2026Article
- Improved patient models for simulation of clinically realisticEJNMMI physics · 2026Article
- Evaluation of segmentation accuracy and the improvement of time effectiveness using deep learning-based segmentation inEJNMMI physics · 2026Article
- Biological Sex Influences the Pharmacokinetics and Organ Dosimetry ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Modelling the relative precision of whole-kidney dosimetry in molecular radiotherapy using a power law approach.Radiation protection dosimetry · 2026Article
- Sex-dependent PRRT toxicity in patients with metastatic somatostatin receptor-avid neuroendocrine tumors treated withHormones (Athens, Greece) · 2026Article
- Global insights into [Scientific reports · 2026Article
- Toward the standardization of radiopharmaceutical therapies: a technical note evaluating a clinical dosimetry workflow for single-time-pointEJNMMI physics · 2025Article
- Blood-based transcriptomic biomarkers for response to [EJNMMI research · 2025Article
- Evaluation of using small volume of interest regions for clinical kidney dosimetry inEJNMMI physics · 2025Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo present data from an interim analysis of a Phase II trial designed to determine the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by giving as many cycles as possible within a maximum renal biologically effective dose (BED).
methodTreatment was given with repeated cycles of 7.4 GBq
resultsFifty-one patients were included in the present analysis. Among the patients who received treatment as planned, the median number of cycles in Step 1 was 5 (range 3-7), and for those who completed Step 2 it was 7 (range 5-8); 73% were able to receive >4 cycles. Although GFR decreased in most patients after the completion of treatment, no grade 3-4 toxicity was observed. Patients with a reduced baseline GFR seemed to have an increased risk of GFR decline. Five patients received treatment in Step 2, none of whom exhibited a significant reduction in renal function.
conclusionsIndividualising PRRT using renal dosimetry seems feasible and safe and leads to an increased number of cycles in the majority of patients. The trial will continue as planned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.